Oliver Hartley

Oliver Hartley

Company: Orion Biotechnology

Job title: VP - Drug Discovery


Orion Biotechnology: Unlocking the Therapeutic Potential of Complex GPCRs Using a Novel Modality 12:30 pm

Unlocking the therapeutic potential of GPCRs with a novel drug modality and purpose-built discovery platform Addresses previously undruggable GPCR targets by precision engineering ligands of peptide and protein GPCRs to develop analogs with superior binding affinity, potency, and pharmacological control, offering significant advantages over small molecule and antibody approaches Advancing a diversified pipeline of potential…Read more

day: Day Two

Panel Discussion: Leveraging Human Genetics for Hit-to-Lead Optimization & Effective GPCR-Target Discovery 12:00 pm

Creating target discovery platforms based on genetic human data for better hit-to-lead optimization is at the forefront of early drug discovery pipelines across biotech and pharma industries. We will explore the learnings from Regeneron’s key candidate GPR75 and how to inform, develop and expedite the drug discovery process for clinical success. Leveraging the UK Biobank…Read more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.